Image courtesy of FrameAngel at FreeDigitalPhotos.net
According to a new study, mental health problems like anxiety and depression may explain why people with rheumatoid arthritis (RA) have an increased risk of cardiovascular disease. According to the study, anger, anxiety, depressive symptoms, job stress and low social support was linked to increasing risk of hardening of the arteries, or atherosclerosis for people with RA.
In the study, Dr. Jon T. Giles of Columbia University College of Physicians and Surgeons in New York City and team compared 195 patients with RA and no history of heart problems to more than 1,000 similar adults without arthritis. Study participants with RA had more depressive symptoms, higher personal (such as caring for a loved one) and health stress, higher job stress and lower relationship stress. These listed psychosocial problems, on top of higher anxiety scores and anger scores, were associated with increased odds of coronary artery calcium. Furthermore, job stress increased the risk of plaque in the carotid artery in the neck, which helps supply blood to the brain. In the comparison group, there was no relation between the aforementioned psychosocial factors and artery calcium. Continue reading →
ACE has set ambitious goals for its 2015/2016 Work Plan. Our five primary work areas will deliver high impact consumer and public formulary information, programming, advocacy and private payer education across Canada.
The Qualman-Davies Arthritis Consumer Community Leadership Award
Do you know a person with arthritis who has, or is, providing leadership in the community and deserves recognition for their valuable volunteer work? We encourage you to help us celebrate their contributions by nominating them for the Qualman-Davies Arthritis Consumer Community Leadership Award.
The Qualman-Davies Arthritis Consumer Community Leadership Award was created in 2014 to recognize one person’s contributions to helping all Canadians living with the disease to be heard in decision-making processes that affect millions. That’s what Ann Qualman and Jim Davies did as early pioneers in arthritis advocacy in Canada. Their tireless and selfless efforts helped millions of Canadians.
JointHealth™ shareables – Check it out, and feel free to share!
Whether it is with an infographic, video, or on-line booklet, ACE looks for new, user-friendly ways to share information to help its members, subscribers and visitors stay current with popular arthritis and related healthcare topics and issues. With today’s launch of JointHealth™ shareables, we are giving you all three in one convenient spot. Each JointHealth™ shareable will cover a specific topic of interest identified by you, our reader and on-line visitor.
What has ACE done for you lately? Here’s what we’ve been working on.
World Autoimmune Arthritis Day
Hosted by the International Foundation for Autoimmune Arthritis, the World Autoimmune Arthritis Day united dozen of nonprofits, advocates, and experts from around the world to provide educational and awareness information to patients, their supporters, and the general public. ACE participated in this virtual global race and expanded the arthritis conversation online. Continue reading →
Tofacitinib (Xeljanz®) for the treatment of rheumatoid arthritis approved in Quebec.
As of June 1st, tofacitinib (Xeljanz®) for the treatment of moderate to severe rheumatoid arthritis has been listed for coverage on Quebec’s drug formulary. Click here to view the detailed medication criteria.
Tofacitinib is an oral targeted small molecule medicine (TSMM) that was issued a Notice of Compliance (NOC) from Health Canada on April 17, 2014. Tofacitinib in combination with methotrexate (MTX), is indicated for reducing the signs and symptoms of RA, in adult patients with moderately to severely active RA who have had an inadequate response to MTX. In cases of intolerance to MTX, physicians may consider the use of tofacitinib as monotherapy.
Click here to view the most up-to-date version of ACE’s Report Card on provincial formulary reimbursement listings for biologic response modifiers.